Immunohistochemical screening and fluorescence in situ hybridization confirmation of ALK translocation in lung adenocarcinoma and its clinicopathological significance: A single-center large-scale investigation of Chinese patients

Human Pathology

Volumn 45, Issue 7, 2014, Pages 1414-1422

  Wang, Wei Ya ^a   Liang, Dong Ni ^b   Yao, Wen Qing ^a   Wu, Wei Lu ^a   Li, Jin Nan ^a   Chen, Min ^a   Liao, Dian Ying ^a   Zhang, Mei ^c   Li, Gan Di ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c Sichuan Province Medical Technology Consulting Office   (China)

Author keywords

ALK; Anaplastic lymphoma kinase; FISH; Lung adenocarcinoma; Translocation

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CHINESE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE TRANSLOCATION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCUS SECRETION; SIGNET RING CARCINOMA; WILD TYPE;

ALK; ANAPLASTIC LYMPHOMA KINASE; FISH; LUNG ADENOCARCINOMA; TRANSLOCATION;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHINA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 84903219506     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2014.02.015     Document Type: Article

References (35)

1. K. Shibuya, C.D. Mathers, and C. Boschi-Pinto et al. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000 BMC Cancer 2 2002 37
2. R.S. Herbst, J.V. Heymach, and S.M. Lippman Lung cancer N Engl J Med 359 2008 1367 1380
3. T. Colvy, M. Noguchi, and C. Henschke et al. Adenocarcinoma W.D. Travis, E. Brambilla, H.K. Muller-Hermelink, C.C. Harris, World Health Organization classification of tumors: pathology and genetics. Tumours of the lung, pleura, thymus and heart 2004 IARC Press Lyon, France 35 44
4. J.G. Paez, P.A. Janne, and J.C. Lee et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500 (Pubitemid 38720929)
5. L.V. Sequist, V.A. Joshi, and P.A. Janne et al. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing Oncologist 12 2007 90 98 (Pubitemid 46143506)
6. H. Ji, D. Li, and L. Chen et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies Cancer Cell 9 2006 485 495 (Pubitemid 43832191)
7. M. Soda, Y.L. Choi, and M. Enomoto et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561 566 (Pubitemid 47206930)
8. K. Rikova, A. Guo, and Q. Zeng et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer Cell 131 2007 1190 1203 (Pubitemid 350235027)
9. D.W. Wong, E.L. Leung, and K.K. So et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS Cancer 115 2009 1723 1733
10. J.M. Boland, S. Erdogan, and G. Vasmatzis et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas Hum Pathol 40 2009 1152 1158
11. E.L. Kwak, Y.J. Bang, and D.R. Camidge et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 2010 1693 1703
12. F. Janku, D.J. Stewart, and R. Kurzrock Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat Rev Clin Oncol 7 2010 401 414
13. R. Jokoji, T. Yamasaki, and S. Minami et al. Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma J Clin Pathol 63 2010 1066 1070
14. A. Yoshida, K. Tsuta, and S. Watanabe et al. Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component Lung Cancer. 72 2011 309 315
15. A.T. Shaw, B.Y. Yeap, and M. Mino-Kenudson et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK J Clin Oncol 27 2009 4247 4253
16. J.P. Koivunen, C. Mermel, and K. Zejnullahu et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer Clin Cancer Res 14 2008 4275 4283
17. K. Inamura, K. Takeuchi, and Y. Togashi et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset Mod Pathol 22 2009 508 515
18. D.R. Camidge, S.A. Kono, and A. Flacco et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment Clin Cancer Res 16 2010 5581 5590
19. X. Zhang, S. Zhang, and X. Yang et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression Mol Cancer 9 2010 188
20. A. McLeer-Florin, D. Moro-Sibilot, and A. Melis et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study J Thorac Oncol 7 2012 348 354
21. M. Mino-Kenudson, L.R. Chirieac, and K. Law et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry Clin Cancer Res 16 2010 1561 1571
22. J.H. Paik, G. Choe, and H. Kim et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization J Thorac Oncol 6 2011 466 472
23. E.S. Yi, J.M. Boland, and J.J. Maleszewski et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH J Thorac Oncol 6 2011 459 465
24. W.D. Travis, E. Brambilla, and M. Noguchi et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma J Thorac Oncol 6 2011 244 285
25. W.Y. Wang, L. Gu, and W.P. Liu et al. ALK-positive extramedullary plasmacytoma with expression of the CLTC-ALK fusion transcript Pathol Res Pract 207 2011 587 591
26. S. Perner, P.L. Wagner, and F. Demichelis et al. EML4-ALK fusion lung cancer: a rare acquired event Neoplasia 10 2008 298 302 (Pubitemid 351328588)
27. M.P. Martelli, G. Sozzi, and L. Hernandez et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues Am J Pathol 174 2009 661 670
28. K. Takeuchi, Y.L. Choi, and Y. Togashi et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer Clin Cancer Res 15 2009 3143 3149
29. S. Popat, D. Gonzalez, and T. Min et al. ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma Lung Cancer 75 2012 300 305
30. S.J. Rodig, M. Mino-Kenudson, and S. Dacic et al. Unique clinicopathologic features characterize ALK rearranged lung adenocarcinoma in the Western population Clin Cancer Res 15 2009 5216 5223
31. A. Yoshida, K. Tsuta, and H. Nakamura et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas Am J Surg Pathol 35 2011 1226 1234
32. D.R. Camidge, Y.J. Bang, and E.L. Kwak et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study Lancet Oncol 13 2012 1011 1019
33. Y. Koh, D.W. Kim, and T.M. Kim et al. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors J Thorac Oncol 6 2011 905 912
34. S.G. Wu, Y.W. Kuo, and Y.L. Chang et al. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR J Thorac Oncol 7 2012 98 104
35. P. Yang, K. Kulig, and J.M. Boland et al. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma J Thorac Oncol 7 2012 90 97